252 related articles for article (PubMed ID: 29912514)
1. [The opinion of the Expert Group of the Polish Society of Ophthalmology on using nepafenac in the prevention of postoperative macular edema after cataract surgery in diabetic patients].
Grabska-Liberek I; Bakunowicz-Łazarczyk A; Malukiewicz G; Misiuk-Hojło M; Mrukwa-Kominek E; Romaniuk W; Romanowska-Dixon B; Jurowski P; Kęcik D; Lubiński W; Omulecki W; Szaflik J; Szaflik JP; Pietruszyńska M; Karska-Basta I; Stafiej J; Gosławski W
Klin Oczna; 2016; 118(2):155-60. PubMed ID: 29912514
[TBL] [Abstract][Full Text] [Related]
2. Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1% treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy.
Pollack A; Staurenghi G; Sager D; Mukesh B; Reiser H; Singh RP
Br J Ophthalmol; 2017 Apr; 101(4):423-427. PubMed ID: 27388251
[TBL] [Abstract][Full Text] [Related]
3. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac.
Lindstrom R; Kim T
Curr Med Res Opin; 2006 Feb; 22(2):397-404. PubMed ID: 16466612
[TBL] [Abstract][Full Text] [Related]
4. Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac.
Wolf EJ; Braunstein A; Shih C; Braunstein RE
J Cataract Refract Surg; 2007 Sep; 33(9):1546-9. PubMed ID: 17720068
[TBL] [Abstract][Full Text] [Related]
5. Prospective, Randomized Study Comparing the Effect of 0.1% Nepafenac and 0.4% Ketorolac Tromethamine on Macular Thickness in Cataract Surgery Patients With Low Risk for Cystoid Macular Edema.
Ramakrishnan S; Baskaran P; Talwar B; Venkatesh R
Asia Pac J Ophthalmol (Phila); 2015; 4(4):216-20. PubMed ID: 26225780
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy and patients' tolerability of Nepafenac and Ketorolac in the treatment of ocular inflammation following cataract surgery: A meta-analysis of randomized controlled trials.
Zhao X; Xia S; Wang E; Chen Y
PLoS One; 2017; 12(3):e0173254. PubMed ID: 28253334
[TBL] [Abstract][Full Text] [Related]
7. Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery.
Zaczek A; Artzen D; Laurell CG; Stenevi U; Montan P
J Cataract Refract Surg; 2014 Sep; 40(9):1498-505. PubMed ID: 25135542
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of addition of nepafenac 0.1% to steroid eye drops in prevention of post-phaco macular edema in high-risk eyes.
El Gharbawy SA; Darwish EA; Abu Eleinen KG; Osman MH
Eur J Ophthalmol; 2019 Jul; 29(4):453-457. PubMed ID: 30203671
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis of macular edema after cataract surgery in diabetic patients, topical Nepafenac versus intravitreal Ranibizumab.
Howaidy A; Eldaly ZH; Anis M; Othman TM
Eur J Ophthalmol; 2022 Jan; 32(1):205-212. PubMed ID: 33726537
[TBL] [Abstract][Full Text] [Related]
10. Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema.
Mathys KC; Cohen KL
Eye (Lond); 2010 Jan; 24(1):90-6. PubMed ID: 19229275
[TBL] [Abstract][Full Text] [Related]
11. Topical nonsteroidal anti-inflammatory drugs as adjuvant therapy in the prevention of macular edema after cataract surgery.
Cardascia N; Palmisano C; Centoducati T; Alessio G
Int Ophthalmol; 2017 Oct; 37(5):1127-1131. PubMed ID: 27766540
[TBL] [Abstract][Full Text] [Related]
12. Pseudophakic cystoid macular edema prevention and risk factors; prospective study with adjunctive once daily topical nepafenac 0.3% versus placebo.
McCafferty S; Harris A; Kew C; Kassm T; Lane L; Levine J; Raven M
BMC Ophthalmol; 2017 Feb; 17(1):16. PubMed ID: 28219426
[TBL] [Abstract][Full Text] [Related]
13. Topical nepafenac as an alternate treatment for cystoid macular edema in steroid responsive patients.
Warren KA; Fox JE
Retina; 2008; 28(10):1427-34. PubMed ID: 18664937
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory Medication of Cataract Surgery in Pseudoexfoliation Syndrome - NSAID Is Needed.
Ilveskoski L; Taipale C; Tuuminen R
Curr Eye Res; 2020 Jul; 45(7):814-819. PubMed ID: 31801388
[TBL] [Abstract][Full Text] [Related]
15. Cystoid and diabetic macular edema treated with nepafenac 0.1%.
Hariprasad SM; Callanan D; Gainey S; He YG; Warren K
J Ocul Pharmacol Ther; 2007 Dec; 23(6):585-90. PubMed ID: 18001248
[TBL] [Abstract][Full Text] [Related]
16. Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 Studies.
Singh RP; Lehmann R; Martel J; Jong K; Pollack A; Tsorbatzoglou A; Staurenghi G; Cervantes-Coste Cervantes G; Alpern L; Modi S; Svoboda L; Adewale A; Jaffe GJ
Ophthalmology; 2017 Jun; 124(6):776-785. PubMed ID: 28268098
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo-controlled randomised study.
Tzelikis PF; Vieira M; Hida WT; Motta AF; Nakano CT; Nakano EM; Alves MR
Br J Ophthalmol; 2015 May; 99(5):654-8. PubMed ID: 25385061
[TBL] [Abstract][Full Text] [Related]
18. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye.
Chastain JE; Sanders ME; Curtis MA; Chemuturi NV; Gadd ME; Kapin MA; Markwardt KL; Dahlin DC
Exp Eye Res; 2016 Apr; 145():58-67. PubMed ID: 26474497
[TBL] [Abstract][Full Text] [Related]
19. Intraindividual comparison of nepafenac 0.3% for the prevention of macular edema after phacoemulsification.
Tzelikis PF; Morato CS; Neves NT; Hida WT; Alves MR
J Cataract Refract Surg; 2018 Apr; 44(4):440-446. PubMed ID: 29685777
[TBL] [Abstract][Full Text] [Related]
20. Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery.
Miyake K; Ota I; Miyake G; Numaga J
J Cataract Refract Surg; 2011 Sep; 37(9):1581-8. PubMed ID: 21855758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
